Home » 2019 » August » 07

Khiron selects Éxito to expand Kuida brand presence in Colombia

Khiron selects Éxito to expand Kuida brand presence in Colombia

Cannabis company Khiron Life Sciences has signed a distribution agreement with retail company Grupo Éxito to increase the former’s Kuida brand’s consumer reach in Colombia. With a potential expansion planned across the country, the deal includes the initial sale of Kuida in five Éxito WOW concept stores and 16 traditional format stores. Khiron CEO Alvaro […]

Khiron selects Éxito to expand Kuida brand presence in Colombia

Khiron selects Éxito to expand Kuida brand presence in Colombia

Cannabis company Khiron Life Sciences has signed a distribution agreement with retail company Grupo Éxito to increase the former’s Kuida brand’s consumer reach in Colombia. With a potential expansion planned across the country, the deal includes the initial sale of Kuida in five Éxito WOW concept stores and 16 traditional format stores. Khiron CEO Alvaro […]

Macquarie to acquire Currenta from Bayer and Lanxess for €3.5bn

Macquarie to acquire Currenta from Bayer and Lanxess for €3.5bn

German pharma company Bayer and specialty chemicals company Lanxess have signed corresponding agreements with Macquarie Infrastructure and Real Assets (MIRA) to sell their stakes in Currenta, a chemical park operator, for an enterprise value of €3.5 billion. Currenta, a joint venture of Bayer and Lanxess, manages and operates infrastructure, energy supply and other essential services […]

Alliant Insurance Services acquires Oklhaoma-based Fred Daniel & Sons

Alliant Insurance Services acquires Oklhaoma-based Fred Daniel & Sons

Insurance acquisition news : US specialty insurance brokerage company Alliant Insurance Services has acquired Oklahoma-based insurance agency Fred Daniel & Sons for an undisclosed price to strengthen its southwest presence. According to Alliant Insurance Services, the Tulsa-based Fred Daniel & Sons brings close to 100 years of experience and a legacy of excellence in commercial […]

Stokes’ STK-001 secures FDA orphan drug designation for Dravet Syndrome

Stokes’ STK-001 secures FDA orphan drug designation for Dravet Syndrome

US biotech company Stoke Therapeutics has secured orphan drug designation for its lead product candidate – STK-001 from the US Food and Drug Administration (FDA) for the treatment for Dravet syndrome. Considered to be a severe and progressive genetic epilepsy, Dravet syndrome is characterized by frequent, prolonged and refractory seizures that start within the first […]

The post Stokes’ STK-001 secures FDA orphan drug designation for Dravet Syndrome appeared first on PharmaNewsDaily.com.